

Pondaplin: A Novel Cyclic Prenylated Phenylpropanoid from *Annona glabra*

Xiao-Xi Liu[†], Elsa Pilarinou,[♦] and Jerry L. McLaughlin^{†*}

[†] Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907, USA; [♦] Walker Cancer Research Institute, 1634A Metropolitan Blvd., Tallahassee, Florida 32308, USA

Received 21 September 1998; revised 2 November 1998; accepted 3 November 1998

Abstract: A novel cyclic prenylated phenylpropanoid, pondaplin was isolated from the ethanolic extracts of the leaves of *Annona glabra*, by directing the fractionation with the brine shrimp lethality test (BST). Pondaplin showed selective cytotoxicities at moderate potencies among six human solid tumor cell lines.

© 1998 Published by Elsevier Science Ltd. All rights reserved.

Keywords: natural products, antitumor compounds

Annona glabra L. (Annonaceae), commonly known as pond apple, is a tropical tree distributed mainly in the Americas and in southeast Asia. It is used in traditional medicine as an insecticide and a parasiticide.^{1, 2} Several bioactive Annonaceous acetogenins have been previously isolated from this species.^{1, 3-5} As part of our continuing efforts to find new and structurally diverse bioactive leads, a novel cyclic prenylated phenylpropanoid, pondaplin (**1**), was isolated from the bioactive ethanolic extracts of the leaves, obtained from trees native to Florida, using bioactivity-directed fractionation with the brine shrimp lethality test (BST).^{6, 7} The structure of **1** (Figure 1) was identified as a cyclic prenylated *p*-coumarate by NMR spectroscopic techniques (Table 1, Figure 2). The new compound demonstrated moderate cytotoxicities among six human solid tumor cell lines with selectivities for the breast (MCF-7) and prostate (PC-3) cancer cell lines (Table 2).




Figure 1. Structure of Pondaplin (**1**).

Compound **1** was isolated as colorless crystals, m. p. 194–195 °C. Its molecular weight was suggested by the peak at m/z 231 $[MH]^+$ in the CIMS. The HRCIMS gave m/z 231.1018 for the $[MH]^+$ ion (calcd. 231.1021) corresponding to the molecular formula, $C_{14}H_{14}O_3$.

Compound **1** showed a UV λ_{max} at 245 nm ($\log \epsilon = 3.05$) with a shoulder at 295 nm ($\log \epsilon = 3.03$) and aromatic (3040, 1603, and 1513 cm^{-1}) and carbonyl (1709 cm^{-1}) absorption peaks in its IR spectrum. The presence of a *para*-substituted aromatic system was suggested by δ_{H} 7.58 (dd, $J=9.0$ Hz, 2.0 Hz, H-3/5) and δ_{H} 6.80 (dd, $J=8.5$ Hz, 2.0 Hz, H-2/6) in the NMR (Table 1). This was confirmed by the ^{13}C chemical shifts at δ_{C} 157.99 (C-1), 114.94 (C-2/6), 132.97 (C-3/5), and 126.46 (C-4). The linkage of the double bond (C-7/8) to the aromatic system was indicated by single-relay COSY data. The linkage was confirmed because the olefinic doublets at δ_{H} 6.87 (H-7) and δ_{H} 5.82 (H-8) showed HMBC correlations to aromatic carbons at δ_{C} 132.97 (C-3/5) and to δ_{C} 126.46 (C-4), respectively (Figure 2).




Figure 2. Selected HMBC correlations in **1**

The presence of an ester linkage in **1** was indicated by the carbonyl carbon signal at δ_{C} 166.59 together with IR absorption at 1709 cm^{-1} . The HMBC correlations between the signal of H-7 (δ_{H} 6.87) and the carbonyl group (δ_{C} 166.59) suggested that the carbonyl group must be located at C-9.

Table 1. ^{13}C NMR and ^1H NMR (δ , J in Hz) of **1**.

	^{13}C NMR (125 MHz)	^1H (500 MHz) (J in Hz)
1	157.99	-
2	114.94	6.80 (dd, 9.0, 2.0)
3	132.97	7.58 (dd, 8.5, 2.0)
4	126.46	-
5	132.97	7.58 (d, 9.0)
6	114.94	6.80 (d, 9.0)
7	144.21	6.87 (d, 12.0)
8	116.06	5.82 (d, 12.5)
9	166.59	-
1'	58.53	4.17 (d, 7.0)
2'	126.97	5.62 (td, 6.5, 1.5)
3'	132.19	-
4'	68.77	4.54 (s)
5'	13.83	1.67 (s)

The remaining four resonances at δ_{H} 5.62 (1H, td, $J=6.5$ Hz, 1.5, H-2'), 4.54 (2H, s, H-4'), 4.17 (2H, d, $J=7.0$ Hz, H-1'), and 1.67 (3H, s, H-5') and five peaks at δ_{C} 132.19 (C-3'), 126.97 (C-2'), 68.77 (C-4'), 58.53 (C-1'), and 13.83 (C-5') in the NMR spectra (Table 1) were characteristic spectral features for the oxygen-substituted prenyl group, which was

confirmed by HMBC correlations among H-1'/C-3', H-4'/C-2', H-4'/C-3', H-5'/C-2', H-5'/C-3', and H-5'/H-4' (Figure 2).

The linkage between the ester group and the prenyl group was established via HMBC correlation between the methylene group (H-4') and the carbonyl carbon (C-9). The presence of an additional downfield-shifted methylene carbon signal at δ_C 58.53 (C-1') could only be accounted for by its connection to an oxygen atom. This was also revealed by the 1H shifts of H-2/6 (δ_H 6.80) and the ^{13}C NMR shift of C-1 (δ_C 157.99) in the aromatic system.

The coupling constant of the pair of olefinic protons at δ_H 6.87 (H-7, br d, $J=12.0$ Hz) and 5.82 (H-8, br d, $J=12.5$ Hz) indicated the (*Z*)-configuration for the double bond at C-7/8. The stereochemistry of the other double bond (C-2'/3') was suggested by NOESY data. In the NOESY spectrum, the triple doublet signal of olefinic protons at δ_H 5.62 showed a cross peak to the methyl group (δ_H 1.67, s, 3H, H-5'), which indicated the (*Z*)-configuration.

Many of phenylpropanoids exhibit diverse biological activities of which the most noteworthy are antimicrobial, anticancer, and hypotensive properties.⁸⁻¹⁰ Moreover, phenylpropanoid derivatives are already known to inhibit some enzymes such as cAMP phosphodiesterase and prostaglandin synthetase.^{11, 12} The biological activities of **1** against six solid tumor cell lines are summarized in Table 2. The compound was moderately and selectively active across the six human tumor cell lines in our seven-day MTT human solid tumor cytotoxicity tests.¹³ Since this is a small molecule and total synthesis should not be difficult, structural modifications with possible enhancement of bioactivity seems reasonable.

Table 2. Bioactivity of **1**.

Compound		1	adriamycin ^g
BST ¹ ED ₅₀ (μ g/ml)		3.9×10^1	-
Human	A-549 ^a	1.1×10^1	1.5×10^{-3}
Tumor	MCF-7 ^b	2.3	1.1×10^{-1}
Cell	HT-29 ^c	5.0	2.6×10^{-2}
Lines	A-498 ^d	2.6×10^1	3.0×10^{-3}
ED ₅₀	PC-3 ^e	3.6	1.9×10^{-2}
(μ g/ml)	PACA-2 ^f	1.9×10^1	1.6×10^{-3}

¹Brine shrimp lethality test; ⁶ ^a Human lung carcinoma; ^b Human breast carcinoma; ^c Human colon adenocarcinoma; ^d Human kidney carcinoma; ^e Human prostate adenocarcinoma; ^f Human pancreatic carcinoma; ^g positive control standard.

Acknowledgments. This investigation was supported by RO1 grant No. CA 30909 from the National Cancer Institute, NIH. Thanks are due to the Purdue Cell Culture Laboratory, Purdue Cancer Center, for the cytotoxicity testing. X. Liu acknowledges fellowship support from the Purdue Research Foundation.

References and Notes

1. Ohsawa, K.; Atsuzawa, S.; Mitsui, T.; Yamamoto, I. *J. Pesticide Sci.* **1991**, *16*, 93-96.
2. Padmaja, V.; Thankamany, K.; Hara, N.; Fujimoto, Y.; Hisham, A. *J. Ethnopharmacol.* **1995**, *48*, 21-24.
3. Liu, X.; Alali, F. Q.; Craig, D. C.; Rogers, L.; Pilarinou, E.; McLaughlin, J. L. *Bioorganic. Med. Chem.* **1998**, *6*, 959-966
4. Liu, X.; Alali, F. Q.; Pilarinou, E.; McLaughlin, J. L. *J. Nat. Prod.* **1998**, *61*, 620-624
5. Liu, X.; Alali, F. Q.; Pilarinou, E.; McLaughlin, J. L. *Phytochem.* **1998**, In press
6. McLaughlin, J. L. in *Methods in Plant Biochemistry*. Hostettmann, K., Ed.; Academic Press: London, 1991, Vol. 6, pp. 1-33.
7. The leaves of *Annona glabra* L. were collected in Florida in May, 1996. The plant material was collected and identified by one of us (Dr. Elsa Pilarinou). A voucher specimen is deposited in the Pharmacognosy Herbarium.
8. Ducki, S.; Hadfield, J. A.; Lawrence, N. J.; Liu, C.-Y.; McGown, A. T.; Zhang, X. *Planta Med.* **1996**, *62*, 185-186.
9. Ojewole, J. A. O.; Adesina, S. K. *Planta Med.* **1983**, *49*, 46-50.
10. Perez, C.; Almonacid, L. N.; Trujillo, J. M.; Gonzalez, A. G.; Alonso, S. J.; Navarro, E. *Planta Med.* **1995**, *61*, 535-536.
11. Kitarawa, S.; Tsukamoto, H.; Hisada, S.; Nhisibe, S. *Chem. Pharm. Bull.* **1984**, *32*, 1209-1213.
12. Hussein, M.; Samuelsson, G. *Planta Med.* **1992**, *58*, 14-18.
13. *In vitro* cytotoxicities, against human tumor cell lines, were carried out at the Purdue Cancer Center, Cell Culture Laboratory, using standard 7-day MTT assays for A-549 (human lung carcinoma), MCF-7 (human breast carcinoma), HT-29 (human colon adenocarcinoma), A-498 (human kidney carcinoma), PC-3 (human prostate adenocarcinoma) and PACA-2 (human pancreatic carcinoma). Adriamycin is always used as a positive antitumor control in the same runs; ED₅₀ values of ≤ 4 $\mu\text{g/ml}$ are considered significantly active.